Skip to main content

Table 7 Budget impact

From: Budget impact analysis of the use of extended half-life recombinant factor VIII (efmoroctocog alfa) for the treatment of congenital haemophilia a: the Italian National Health System perspective

 

Overall num. Patients

Num. patients treated with efmoroctocog alfa

Cost CE (Euro)

Cost NE (Euro)

Savings (Euro)

% Savings

Year 1

 Pediatrics

169

17

11,812,558

11,686,364

126,194

1.1%

 Adults

691

69

172,352,752

169,523,751

2,829,001

1.6%

 Total

860

86

184,165,311

181,210,115

2,955,196

1.6%

Year 2

 Pediatrics

170

26

11,871,934

11,681,691

190,243

1.6%

 Adults

694

104

173,219,079

168,954,248

4,264,831

2.5%

 Total

864

130

185,091,013

180,635,939

4,455,074

2.4%

Year 3

 Pediatrics

171

34

11,931,608

11,676,676

254,932

2.1%

 Adults

698

140

174,089,760

168,374,735

5,715,025

3.3%

 Total

869

174

186,021,368

180,051,411

5,969,957

3.2%

Total

 Pediatrics

510

77

35,616,100

35,044,731

571,369

1.6%

 Adults

2083

313

519,661,591

506,852,735

12,808,856

2.5%

 Total

2593

390

555,277,691

541,897,466

13,380,225

2.4%